PDGFRB and Miyoshi myopathy: Nevertheless, despite dasatinib cannot be considered a proper anti-angiogenic TKIs, based on the constitutive activation of both PDGFR and SRC kinases in MMECs and MM cells, it efficiently reduces tumor growth and angiogenesis in vitro and in vivo studies in MM xenograft model.